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Edited by Barry HalliwellAbstract Ab is the major component of amyloid in the brain in
Alzheimer’s disease and is derived from Alzheimer amyloid
precursor protein (APP) by sequential proteolytic cleavage
involving a-, b- and c-secretase. Recently, c-secretase was shown
to cleave near the cytoplasmic membrane boundary of APP
(called the e-cleavage), as well as in the middle of the membrane
domain (c-cleavage). However, the precise relationship between
c- and e-cleavage is still unknown. In this paper, I analyzed
Ab-related peptides using immunoprecipitation and liquid chro-
matography ion trap mass spectrometer and found some long
Ab-related peptides, starting at Ab residues 16Lys–23Asp and
ending at 43Thr–52Leu, in the culture media of COS-1 cells and
in human brain extract. These results indicated that longer Ab-
related peptides cleaved at e-cleavage site were secreted under
normal conditions and were dependent on the a-secretase
cleavage products.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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A signiﬁcant accumulation of Ab amyloid is a major path-
ological feature in the brain in patients with Alzheimer’s dis-
ease (AD). Amyloid precursor protein (APP) is cleaved by
either a- or b-secretase, resulting in secretion of the N-terminal
extracellular domain of this protein. Then, the remaining
membrane-anchored C-terminal fragment (C83, a-secretase
product or C99, b-secretase product) releases P3 or Ab by c-
secretase cleavage in the middle of the transmembrane domain.
This cleavage generates the APP intracellular domain (AICD).
Therefore, Ab is believed to be derived from APP by sequential
proteolytic processing involving b- and c-secretase (Fig. 1,
reviewed in [1]).
However, recent reports indicate that AICD is generated by
a proteolytic cleavage between amino acids 49 and 50 of the
Ab domain near the cytoplasmic membrane boundary of C-
terminal fragment (named e-cleavage, Fig. 1), rather than by a
proteolytic cleavage at the c-cleavage site in the middle of the
membrane domain [2–4]. In addition, AICD binds to a DNA
binding protein, Fe65, and translocates to the nucleus [5]. This* Fax: +81-3-3329-8035.
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doi:10.1016/j.febslet.2004.06.034suggests that like the Notch intracellular domain, AICD plays
a role in signal transduction [6]. It has also been reported that
c- and e-cleavage are clearly dependent on presenilin-1 [3,4,7].
However, the precise relationship between c- and e-cleavage is
unknown. For many studies related to pathogenesis of AD, it
is necessary to determine the relationship between c- and e-
cleavage. To clarify this relationship, I have been studying
APP metabolic pathway. In this paper, I analyzed Ab-related
peptide in the culture media of COS-1 cells and in human brain
extract, using immunoprecipitation and liquid chromatogra-
phy ion trap mass spectrometer (LC/MS/MS). Long Ab-re-
lated peptides processed at e-cleavage site were secreted under
normal conditions.2. Materials and methods
2.1. Cell culture and transfection
COS-1 cells were cultured as described previously [8]. The C83 and
C99 constructs have been reported [9]. Transient expressions of these
constructs in COS-1 cells were achieved using LipofectAMINE 2000
(Invitrogen Corp., Carlsbad, CA) following the manufacturer’s in-
structions. After transfection, COS-1 cells were cultured for 72 h and
then the culture medium was used for LC/MS/MS analysis.
2.2. SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
Metabolic labeling with [35S]methionine and immunoprecipitation
with antibodies to APP C-terminus, R37 [10], and to Ab 17–31, E50
[11], were carried out as described previously [8]. The associated Ab-
related peptides were separated in a 12.5% polyacrylamide gel using
Tris–tricine system [12]. After electrophoresis, the gel was dried and
processed for autoradiography using BAS 3000 (Fuji Photo Film Co.,
Ltd., Tokyo).
2.3. Immunoprecipitation of Ab-related peptides from the culture
medium
The capture antibody, E50 (20 ll), was added to 1 ml of the culture
medium. After incubation at 4 C for 16 h, 30 ll of UltraLink Im-
mobilized protein A/G (Pierce, Rockford, IL) was added. The mixture
was shaken for 2 h and centrifuged at 5000 g for 5 min. The resulting
precipitate was washed with 50 mM Tris–HCl/150 mM NaCl, pH 7.6
(TBS). Immunoreactive Ab-related peptides were extracted from the
resin with 30% formic acid/20% acetonitrile solution. The extract
was ﬁltered through a Microcon YM-50 membrane ﬁlter (Millipore,
Billerica, MA), diluted, and dried in a Speedvac. The resulting extract
was dissolved in 50 ll of 2% formic acid/2% acetonitrile solution.
2.4. Immunoprecipitation of Ab-related peptides from human brain
extract
Human brain tissue (0.45 g cortex from a 75-year-old normal male)
was homogenized with a Teﬂon-glass homogenizer in 9 vol of 0.25 M
sucrose/10 mM Tris–HCl, pH 7.6, containing protease inhibitor
cocktail. After centrifugation at 105 000 g for 60 min, the superna-
tant fraction (1 ml) was used for the immunoprecipitation with E50
(20 ll) as described above.blished by Elsevier B.V. All rights reserved.
Fig. 2. The generation of APP C-terminal fragments, C83 and C99,
and Ab-related peptides in wild-type COS-1 cells, COS-1 cells trans-
fected with C83 and COS-1 cells transfected with C99. Immunopre-
cipitates with R37 (upper panel) and with E50 (lower panel) were
separated on Tris–tricine system SDS–PAGE. C83, C99 and Ab-re-
lated peptides were shown.
Fig. 1. Schematic diagram of APP and its derivatives. Arrowheads
indicate major cleavage sites of a-, b-, c-, and e-cleavage.
74 F. Kametani / FEBS Letters 570 (2004) 73–762.5. LC/MS/MS analysis
Ten ll of the above extract was applied to a ParadigmMS4 (Microm
BioResources, Inc., Auburn, CA) HPLC system ﬁtted with HTC-PAL
automatic sampler (CHROMSYS LLC, Alexandria, VA). A reverse
phase capillary column (ODS-HG5, 0.15 mm i.d. 50 mm, Nomura
Chemical Co., Ltd., Seto, Japan) was used at a ﬂow rate of 2 ll/min
with a 4–72% linear gradient of acetonitrile in 0.1% formic acid. Eluted
Ab-related peptides were directly detected with ion trap mass spec-
trometer, LCQ Advantage (Themo Electron Corporation, Waltham,
MA). The obtained data were analyzed with SEQUEST (Themo
Electron Corporation, Waltham, MA).Table 1
Ab-related peptides identiﬁed by LC/MS/MS
TIC MW MW observed Numbering
Wild
1.4e6 1886.0 1887.8 21–40
2.1e6 3463.6 3463.3 19–52
C83
3.5e7 1886.0 1885.7 21–40
3.5e7 2825.6 2828.1 21–49
C99
9.5e5 1511.9 1512.6 27–42
3.5e6 1776.2 1778.6 23–43
5.7e7 2724.6 2722.2 23–50
5.7e7 1814.9 1815.1 22–40
8.9e6 1687.8 1689.1 21–38
3.5e7 1886.0 1883.9 21–40
5.9e6 1902.0 1902.4 21–40
9.7e5 2498.4 2497.1 21–46
3.5e7 2825.6 2825.3 21–49
3.5e6 1778.0 1778.6 20–37
5.0e6 1834.9 1834.1 20–38
8.8e5 3818.2 3816.8 16–52
1.1e6 3672.8 3673.7 1–33
2.6e6 4130.0 4130.7 1–38
Human brain
2.1e6 2856.6 2855.1 22–50
8.5e5 2791.3 2791.9 17–44
TIC, total ion current, M*, oxidized Met.3. Results and discussion
As shown in Fig. 2, a faint Ab-related band was observed in
wild-type COS-1 cells, while clear Ab-related bands were ob-
served in COS-1 cells transfected with C83 or C99. To analyze
these Ab-related peptides, I carried out immunoprecipitation
with E50, followed by LC/MS/MS analysis. Immunoprecipi-
tation followed by MS is reliable, easy method for the identi-
ﬁcation and semi-quantiﬁcation of Ab [13–15]. Using this
technique, however, some Ab molecules are indistinguishable,
e.g., Ab 2–41(4326.213, monoisotopic molecular mass) and
3–42 (4326.213), or Ab 6–37 (3454.721) and 5–35 (3454.732).
Therefore, the information of amino acid sequence is necessary
for identifying these peptides. Consequently, I combined theAmino acid sequence
AEDVGSNKGAIIGLMVGGVV
FFAEDVGSNKGAIIGLMVGGVVIATVIVITLVM*L
AEDVGSNKGAIIGLMVGGVV
AEDVGSNKGAIIGLM*VGGVVIATVIVITL
NKGIIGLMVGGVVIA
DVGSNKGAIIGLM*VGGVVIAT
DVGSNKGAIIGLM*VGGVVIATVIVITLV
EDVGSNKGAIIGLMVGGVV
AEDVGSNKGAIIGLMVGG
AEDVGSNKGAIIGLMVGGVV
AEDVGSNKGAIIGLM*VGGVV
AEDVGSNKGAIIGLM*VGGVVIATVIV
AEDVGSNKGAIIGLM*VGGVVIATVIVITL
FAEDVGSNKGAIIGLMVG
FAEDVGSNKGAIIGLMVGG
KLVFFAEDVGSNKGAIIGLM*VGGVVIATVIVITLVM*L
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG
EDVGSNKGAIIGLM*VGGVVIATVIVITLV
LVFFAEDVGSNKGAIIGLM*VGGVVIATV
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analysis. As shown in Table 1, 2, 2, and 14 Ab-related peptides
were identiﬁed in the culture medium of wild-type COS-1 cells,
COS-1 cells transfected with C83, and COS-1 cells transfected
with C99, respectively. The MS/MS data of Ab 21–49 peptide,
which obtained from the culture medium of COS-1 cells
transfected with C83, are shown in Fig. 3. Other Ab-related
peptides were also identiﬁed in the same manner (date not
shown). The N-terminal and C-terminal regions were hetero-
geneous, starting at Ab residues, 1Asp, 16Lys, 19Phe, 20Phe,
21Ala, 22Glu, 23Asp and 27Asn, and ending at Ab residues,Fig. 3. MS/MS analysis data of Ab 21–49 obtained from culture medium of C
spectrum with predicted fragment ion peaks of a candidate peptide is shown33Gly, 37Gly, 38Gly, 40Gly, 42Ala, 43Thr, 46Val, 49Leu,
50Val and 52Leu (Table 1). Some Ab-related peptides were
oxidized at 35Met or 51Met residue. This oxidation might
have occurred in vivo or might have resulted from the ex-
traction process using formic acid [16]. No other post-trans-
lational modiﬁcations were found. Next, Ab-related peptides
in human brain extract were analyzed using the same method.
As shown in Table 1, Ab 22–50 and Ab 17–44 peptides were
identiﬁed in human brain extract.
One peptide in wild-type and C83 COS-1 cells, ﬁve peptides
in C99 COS-1 cells and two peptides in human brain extractOS-1 cells transfected with C83. The correlation of experimental mass
.
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dues Ab 43Thr and 52Leu. These results are supported by a
recent report by Roher et al. [16] in which longer Ab-related
peptides, ending at Ab residues 43–54, existed in amyloid de-
posits from the brains of Val717Phe familial AD individuals.
Of these longer peptides, peptides ending at Ab residues
49Leu, 50Val, and 52Leu were e-cleavage products. As shown
in Table 1, their total ion current (TIC) values indicated that
these peptides were major products. These suggest that e-
cleavage products, as well as c-cleavage products (Ab and p3),
were secreted under normal conditions. Although the precise
relationship between c- and e-cleavage is still unknown, the C-
terminal heterogeneity of longer Ab-related peptides as shown
in Table 1 suggests that carboxypeptidases could have de-
graded the longer Ab to sequentially generate shorter Ab
peptides as described previously [16].
Most of these e-cleavage products have N-termini starting at
Ab residues 17leu–21Ala, suggesting that these were derived
from a-secretase cleavage product, C83. This result is in good
agreement with our previous ﬁnding that AICD production
was preferentially derived from C83 by e-cleavage [9]. Addi-
tionally, I could not detect e-cleavage products, which had N-
termini starting at Ab residues 1Ala–15Gln, in the medium of
COS-1 cells transfected with C99, suggesting that C99 was not
directly processed at e-cleavage site under normal conditions.
Therefore, in COS-1 cells transfected with C83, expressed C83
is directly processed at the e-cleavage site, while in wild-type
COS-1 cells or COS-1 cells transfected with C99, C83 pro-
duced by a-secretase cleavage is processed at the e-cleavage
site.
The relationship between these longer Ab-related peptides
and amyloid ﬁbril formation is interesting. In general, Ab with
a longer C-terminus can more readily polymerize into amyloid
ﬁlaments [1]. However, identiﬁed longer peptides in the culture
media and in brain extract lack the N-terminal region of Ab
(residues 1–16), which is the essential region for amyloid ﬁbril
formation [17]. Therefore, these longer Ab peptides, which are
secreted under normal conditions, may not be involved in
amyloid ﬁbril formation. Recent report that no peptides longer
than 40 and 42 amino acids have been recovered in the amyloid
deposits obtained from sporadic AD supports this hypothesis
[16].
In this experiment, I showed that e-cleavage related to the
production of long Ab-related peptides was dependent on C83.
Additionally, I previously showed that e-cleavage relevant to
the production of AICD was also dependent on C83 [9] and
that c-cleavage related to the production of Ab and p3 was not
dependent on the size of APP C-terminal fragments [8]. These
suggest that c- and e-cleavage in APP are diﬀerently regulated.
Recent report that Ab and AICD production are not tempo-
rally linked events but rather two separately regulated, prote-
olytic events supports my results [18]. It has been reported that
AICD interacts with Fe65 [5] and c-Jun N-terminal kinase
interacting protein-1 [19] to induce gene activation, indicating
that AICD plays a role in signal transduction. Interestingly,
some groups report that some PS1 mutations causing familial
AD inhibit the generation of AICD [20–22]. Therefore, thefailure of e-cleavage on C83 relevant to the production of long
Ab-related peptide and AICD may be involved in the patho-
genesis of AD [9]. Further studies are necessary to clarify the
producing mechanism of Ab-related peptides and the potential
pathological activity.
Finally, the information of amino acid sequences and post-
translational modiﬁcations can be obtained using LC/MS/MS.
I have shown that the combination of immunoprecipitation of
Ab and LC/MS/MS is a sensitive, reliable, and powerful tool
for Ab analysis.
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